Zavesca
5 Topics FoundMiglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J...
Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J...
Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J...
Treatment for Type 1 Gaucher ## Zavesca contains the active ingredient Miglustat. Common side effects may include: nausea, back pain, constipation and weight loss. You can read more here: Do you have any other questions?
1 REPLY Filed under ZavescaZavesca 100 mg Oral Capsule by Actelion Pharmaceuticals Us, Inc. ## Markings: OGT;918;100 ## Shape: Capsule ## Color: White ## Package Codes: 66215-201-90 ## Active Ingredients: Miglustat